PMID- 22338911
OWN - NLM
STAT- MEDLINE
DCOM- 20120412
LR  - 20120220
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 59
IP  - 12
DP  - 2011 Dec
TI  - [Autologous bone marrow cell infusion therapy for liver cirrhosis--now and 
      future].
PG  - 1092-8
AB  - Infused (transplanted) green fluorescent protein (GFP)-positive bone marrow cells 
      (BMCs) migrated into the peri-portal regions of the cirrhotic mouse liver induced 
      continuous CCl4 injection without irradiation (without bone marrow ablation). The 
      infused GFP-positive BMCs differentiated into hepatoblasts detected with 
      Liv2-antibody and then differentiated into albumin-producing hepatocytes. The 
      differentiation "niche" induced by persistent liver damage due to continuous CCl4 
      injection seems to be an essential factor. Microarry analysis showed that at an 
      early stage after BMC infusion through mouse tail vein, the genes related to 
      degradation of extracellular matrix (ECM) e.g. MMP-9 were activated. BMC infusion 
      improved liver fibrosis and the survival rate. Recent our finding indicates that 
      mesencymal bone marrow cells will differentiate to hepatocytes and FGF2 will 
      accelerate this differentiation of BMC to hepatocyte. Based on the results 
      obtained in basic research using the GFP/CCl4 model, human trials are now 
      undergoing. We have done this autologous bone marrow cell infusion therapy for 19 
      patients with advanced liver cirrhosis. The clinical study of liver cirrhosis 
      (LC) cases that underwent autologous bone marrow cell infusion from peripheral 
      vein is as follows. Subjects were LC patients with T.B. of < 3.0 mg/dl, Plt of > 
      5(10(10)/l) and no viable hepatocellular carcinoma by diagnostic imaging. 
      Autologous bone marrow cells (BMCs, 400 ml) were isolated from the ilium under 
      general anesthesia. BMCs were separated by cell washing and were infused via the 
      peripheral vein. After BMC infusion, liver function was monitored by blood 
      examination for 24 weeks. We could follow 9 cases more than 6 months so far. 
      After washing, 5.20 +/- 0.63 x 10(9) BMCs were infused into LC patients. Serum 
      albumin level and total protein were significantly improved at 24 weeks after BMC 
      infusion (p < 0.05). The Child-Pugh score was significantly improved at 4 week 
      and 24 weeks after BMC infusion (p < 0.05). No major adverse effects were noted. 
      In conclusion, autologous BMC infusion might be considered as a novel treatment 
      for advanced LC patients.
FAU - Sakaida, Isao
AU  - Sakaida I
AD  - Department of Gastroenterology & Hepatology, Yamaguchi University, Graduate 
      School of Medicine, Ube 755-8505, Japan. sakaida@yamaguchi-u.ac.jp
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/cytology
MH  - Bone Marrow Transplantation/*methods/*trends
MH  - Cell Differentiation
MH  - Disease Models, Animal
MH  - Extracellular Matrix
MH  - Hepatocytes
MH  - Humans
MH  - Liver Cirrhosis/*therapy
MH  - Matrix Metalloproteinase 9
MH  - Mice
MH  - Transplantation, Autologous
EDAT- 2012/02/22 06:00
MHDA- 2012/04/13 06:00
CRDT- 2012/02/21 06:00
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/04/13 06:00 [medline]
PST - ppublish
SO  - Rinsho Byori. 2011 Dec;59(12):1092-8.